YolTech Therapeutics Announces Successful Completion of Dose Escalation Phase in Phase I Trial of YOLT-201 for ATTR
SHANGHAI, Dec. 21, 2024 /PRNewswire/ -- YolTech Therapeutics today announced updated data from its ongoing Phase I/IIa clinical trial of YOLT-201, a first-in-class CRISPR/Cas9-based in vivo gene-editing therapy for ATTR amyloidosis. The trial has completed dosing in...
[2024/12/20] Gene and Cell Therapy- weekly digest from PackGene
FeaturedNewsArticlesPackGene's NewsletterReceive the latest news and insights to your inbox.About PackGenePackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span...
FDA Approves First Medication for Obstructive Sleep Apnea
SILVER SPRING, Md., Dec. 20, 2024 /PRNewswire/ -- Today, the U.S. Food and Drug Administration approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea (OSA) in adults with obesity, to be used in combination with a...
ISCT Hails Landmark US FDA Approval of RYONCIL as Major Milestone for MSC Field
VANCOUVER, BC, Dec. 20, 2024 /PRNewswire/ - The International Society for Cell & Gene Therapy (ISCT) celebrates the US Food and Drug Administration's (FDA) landmark decision to approve Mesoblast Limited's allogenic, bone marrow-derived mesenchymal stromal cell...
Sangamo and Astellas Collaborate to Advance Neurological Gene Therapies Using AAV Capsid Technology
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a leader in genomic medicine, and Astellas Pharma Inc. (TSE: 4503), a global innovator in life sciences, have partnered under a new license agreement. This collaboration centers around Sangamo’s cutting-edge neurotropic AAV...
TRYNGOLZA™ (olezarsen) approved in U.S. as first-ever treatment for adults living with familial chylomicronemia syndrome as an adjunct to diet
TRYNGOLZA shown to significantly reduce triglycerides and substantially reduce acute pancreatitis events in adults with FCS; a rare, highly debilitating and life-threatening disease Indicated for adults with FCS regardless of genetically or clinically confirmed...
Inceptor Bio and GRIT Bio Announce Strategic Partnership to Advance IB-T101, a Next-Generation Solid Tumor CAR-T Utilizing the OUTLAST™ Platform
SHANGHAI and MORRISVILLE, N.C., Dec. 18, 2024 /PRNewswire/ -- Inceptor Bio, a leading innovator in cell therapy, and GRIT Bio, a clinical-stage immunotherapy developer, today announced a strategic partnership to advance IB-T101, a potentially best-in-class CAR-T...
Proof-of-concept study bioengineers therapeutics for improved cancer treatment
Credit: Pixabay/CC0 Public DomainA team of Children's Medical Research Institute (CMRI) scientists has identified a new method for producing a therapeutic product that has the potential to improve the treatment of cancer. The work by Associate Professor Leszek...
DNA-Based Vaccine Production Provides Best Shot at Profitability
Messenger RNA-based vaccine production has become a major industry focus, thanks to the success of jabs developed during the pandemic. However, under normal circumstances, DNA-based manufacturing may be the better option. Researchers at the Aristotle University of...
Akamis Bio Raises $60 Million for Cancer Gene Therapy, Signs Licensing Deal with Xuanzhu Biopharma
Akamis Bio, a clinical-stage oncology company, has raised $60 million in Series A funding that will drive continued development of NG-350A, a new gene therapy based on its proprietary tumor-specific immuno-gene (T-SIGn®). The new funding will support efforts to take...
FDA Agrees to Accelerated Approval Pathway for Promising Huntington’s Disease Gene Therapy
The U.S. Food and Drug Administration (FDA) has agreed that data from two ongoing Phase 1/2 clinical trials, compared with an external control group of untreated patients, may suffice to support an accelerated approval application for a groundbreaking gene therapy for...
Genprex Receives Safety Review Committee Approval to Advance to Phase 2 Portion of Acclaim-3 Clinical Trial of Reqorsa® Gene Therapy in Combination with Tecentriq® in Extensive Stage Small Cell Lung Cancer
Genprex Completes Phase 1 Dose Escalation Portion of Acclaim-3 Clinical Trial Results from Phase 1 Dose Escalation Demonstrate Favorable Safety Profile of REQORSA and Tecentriq in ES-SCLC Patients AUSTIN, Texas , Dec. 16, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex"...
Popular Services
AAV Packaging Service
AAV Analytical Service
Vector Design